Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Biodel Inc. BIOD -1.82% today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting formulations of recombinant human insulin (RHI).
BIOD-123 and BIOD-125 achieved the Company's target pharmacokinetic, pharmacodynamic and toleration profiles in a Phase 1 clinical trial; BIOD-123 favored as lead product candidate to advance to Phase 2
Projecting initiation of a Phase 2 clinical trial of BIOD-123 in the third calendar quarter of 2012
Continuing development of ultra-rapid-acting insulin analog-based formulations with selection of candidates and initiation of a Phase 1 clinical trial projected in the second half of calendar year 2012
http://www.marketwatch.com/story/bi...-rapid-acting-insulin-formulations-2012-04-15
BIOD-123 and BIOD-125 achieved the Company's target pharmacokinetic, pharmacodynamic and toleration profiles in a Phase 1 clinical trial; BIOD-123 favored as lead product candidate to advance to Phase 2
Projecting initiation of a Phase 2 clinical trial of BIOD-123 in the third calendar quarter of 2012
Continuing development of ultra-rapid-acting insulin analog-based formulations with selection of candidates and initiation of a Phase 1 clinical trial projected in the second half of calendar year 2012
http://www.marketwatch.com/story/bi...-rapid-acting-insulin-formulations-2012-04-15
